CTSA
Basic information
Region (hg38): 20:45890144-45898949
Previous symbols: [ "GSL", "PPGB" ]
Links
Phenotypes
GenCC
Source:
- galactosialidosis (Definitive), mode of inheritance: AR
- galactosialidosis (Definitive), mode of inheritance: AR
- galactosialidosis (Strong), mode of inheritance: AR
- galactosialidosis (Strong), mode of inheritance: AR
- galactosialidosis (Supportive), mode of inheritance: AR
- galactosialidosis (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Galactosialidosis | AR | Biochemical | Cardiac manifestations (eg, valvular anomalies and insufficiency) can be severe, and surveillance (eg, with echocardiogram) may allow early detection of sequalae and treatment; Cytopenias have been described; Renal transplanation has been described as beneficial | Audiologic/Otolaryngologic; Biochemical; Cardiovascular; Gastrointestinal; Hematologic; Musculoskeletal; Neurologic; Ophthalmologic; Renal | 4999185; 3149149; 2148053; 8514852; 7759227; 8725271; 8968752; 9762607; 10944848; 18937050 |
ClinVar
This is a list of variants' phenotypes submitted to
- Combined_deficiency_of_sialidase_AND_beta_galactosidase (479 variants)
- Inborn_genetic_diseases (50 variants)
- not_provided (49 variants)
- not_specified (14 variants)
- CTSA-related_disorder (12 variants)
- Galactosialidosis,_late_infantile (6 variants)
- Galactosialidosis,_early_infantile (3 variants)
- Non-immune_hydrops_fetalis (1 variants)
- Abnormality_of_prenatal_development_or_birth (1 variants)
- Cathepsin_a-related_arteriopathy-strokes-leukoencephalopathy (1 variants)
- Galactosialidosis,_adult (1 variants)
- Lynch_syndrome_1 (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CTSA gene is commonly pathogenic or not. These statistics are base on transcript: NM_000000308.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 139 | 144 | ||||
missense | 131 | 154 | ||||
nonsense | 11 | 10 | 21 | |||
start loss | 1 | 1 | ||||
frameshift | 19 | 11 | 35 | |||
splice donor/acceptor (+/-2bp) | 13 | 14 | ||||
Total | 38 | 44 | 138 | 146 | 3 |
Highest pathogenic variant AF is 0.000170817
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CTSA | protein_coding | protein_coding | ENST00000372484 | 15 | 8677 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
5.90e-9 | 0.963 | 121656 | 227 | 3865 | 125748 | 0.0164 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.481 | 250 | 272 | 0.918 | 0.0000167 | 3235 |
Missense in Polyphen | 52 | 72.558 | 0.71667 | 897 | ||
Synonymous | 1.05 | 101 | 115 | 0.875 | 0.00000708 | 968 |
Loss of Function | 2.08 | 18 | 30.4 | 0.593 | 0.00000145 | 340 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.124 | 0.116 |
Ashkenazi Jewish | 0.00194 | 0.000993 |
East Asian | 0.143 | 0.0655 |
Finnish | 0.0223 | 0.0104 |
European (Non-Finnish) | 0.00162 | 0.000879 |
Middle Eastern | 0.143 | 0.0655 |
South Asian | 0.0420 | 0.0206 |
Other | 0.0280 | 0.0138 |
dbNSFP
Source:
- Function
- FUNCTION: Protective protein appears to be essential for both the activity of beta-galactosidase and neuraminidase, it associates with these enzymes and exerts a protective function necessary for their stability and activity. This protein is also a carboxypeptidase and can deamidate tachykinins. {ECO:0000269|PubMed:1907282}.;
- Disease
- DISEASE: Galactosialidosis (GSL) [MIM:256540]: A lysosomal storage disease associated with a combined deficiency of beta- galactosidase and neuraminidase, secondary to a defect in cathepsin A. All patients have clinical manifestations typical of a lysosomal disorder, such as coarse facies, cherry red spots, vertebral changes, foam cells in the bone marrow, and vacuolated lymphocytes. Three phenotypic subtypes are recognized. The early infantile form is associated with fetal hydrops, edema, ascites, visceromegaly, skeletal dysplasia, and early death. The late infantile type is characterized by hepatosplenomegaly, growth retardation, cardiac involvement, and a normal or mildly affected mental state. The juvenile/adult form is characterized by myoclonus, ataxia, angiokeratoma, mental retardation, neurologic deterioration, absence of visceromegaly, and long survival. {ECO:0000269|PubMed:10944848, ECO:0000269|PubMed:1756715, ECO:0000269|PubMed:8514852, ECO:0000269|PubMed:8968752}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Renin-angiotensin system - Homo sapiens (human);Lysosome - Homo sapiens (human);Neutrophil degranulation;Metabolism of lipids;Post-translational protein modification;Metabolism of proteins;MHC class II antigen presentation;Innate Immune System;Immune System;Metabolism;Adaptive Immune System;De novo fatty acid biosynthesis;Sialic acid metabolism;Synthesis of substrates in N-glycan biosythesis;Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein;Asparagine N-linked glycosylation;Glycosphingolipid metabolism;Sphingolipid metabolism
(Consensus)
Recessive Scores
- pRec
- 0.782
Intolerance Scores
- loftool
- 0.0690
- rvis_EVS
- -0.87
- rvis_percentile_EVS
- 10.73
Haploinsufficiency Scores
- pHI
- 0.789
- hipred
- Y
- hipred_score
- 0.575
- ghis
- 0.581
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.982
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ctsa
- Phenotype
- immune system phenotype; renal/urinary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); liver/biliary system phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype;
Gene ontology
- Biological process
- proteolysis;glycosphingolipid metabolic process;intracellular protein transport;regulation of protein stability;positive regulation of catalytic activity;neutrophil degranulation;proteolysis involved in cellular protein catabolic process;regulation of chaperone-mediated autophagy;negative regulation of chaperone-mediated autophagy
- Cellular component
- extracellular region;nucleoplasm;lysosome;endoplasmic reticulum;membrane;azurophil granule lumen;lysosomal lumen;intracellular membrane-bounded organelle;extracellular exosome;lumenal side of lysosomal membrane
- Molecular function
- carboxypeptidase activity;serine-type carboxypeptidase activity;exo-alpha-sialidase activity;enzyme activator activity